VivoSim Labs, Inc.
$1.54
▲
4.32%
2026-04-21 10:08:00
vivosim.ai
NCM: VIVS
Explore VivoSim Labs, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.02 M
Current Price
$1.54
52W High / Low
$5.3 / $1.25
Stock P/E
—
Book Value
$1.7
Dividend Yield
—
ROCE
-115.61%
ROE
-51.07%
Face Value
—
EPS
$1.76
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
1.44
Debt / Equity
18.28
Current Ratio
2.44
Quick Ratio
3.25
Forward P/E
—
Price / Sales
29.56
Enterprise Value
$0.31 M
EV / EBITDA
-0.03
EV / Revenue
2.15
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | KalVista Pharmaceuticals, Inc. | $20.87 | — | $1.07 B | — | -89% | -121.5% | $21.3 / $9.83 | $-0.05 |
| 2. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
| 3. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 4. | NextCure, Inc. | $11.7 | — | $41.66 M | — | -145.43% | -1.11% | $15.74 / $3.85 | $9.97 |
| 5. | MoonLake Immunotherapeutics | $17.89 | — | $1.32 B | — | -64.61% | -60.78% | $62.75 / $5.95 | $4.27 |
| 6. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 7. | Precigen, Inc. | $4.11 | — | $1.45 B | — | -90.19% | -5.72% | $5.46 / $1.23 | $0.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.03 M | 0.03 M | 0.04 M | 0.05 M | 0.02 M | — |
| Operating Profit | -2.75 M | -2.63 M | -2.92 M | -3.15 M | -3.47 M | — |
| Net Profit | -2.69 M | -2.54 M | -2.84 M | 6.85 M | -3.45 M | — |
| EPS in Rs | -0.93 | -0.88 | -0.98 | 2.37 | -1.19 | -1.68 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.14 M | 0.11 M | 0.37 M | 1.5 M |
| Operating Profit | -12.62 M | -15.09 M | -17.73 M | -11.48 M |
| Net Profit | -2.49 M | -14.67 M | -17.26 M | -11.45 M |
| EPS in Rs | -0.86 | -5.07 | -5.96 | -3.96 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 14.65 M | 6.35 M | 20.31 M | 33.3 M |
| Total Liabilities | 4.16 M | 2.75 M | 4.98 M | 3.09 M |
| Equity | 10.49 M | 3.6 M | 15.33 M | 30.21 M |
| Current Assets | 12.13 M | 3.94 M | 17.05 M | 29.53 M |
| Current Liabilities | 3.74 M | 1.86 M | 3.67 M | 1.38 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.46 M | -14.65 M | -12.41 M | -8.45 M |
| Investing CF | 9.03 M | 0.82 M | -0.97 M | -0.41 M |
| Financing CF | 8.85 M | 1.44 M | 0 M | 0.2 M |
| Free CF | -9.47 M | -14.7 M | -12.8 M | -8.86 M |
| Capex | -0.01 M | -0.04 M | -0.4 M | -0.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 32.11% | -70.54% | -75.33% | — |
| Earnings Growth % | 83.04% | 15% | -50.76% | — |
| Profit Margin % | -1727.78% | -13459.63% | -4664.59% | -763.2% |
| Operating Margin % | -8761.11% | -13840.37% | -4792.16% | -765.27% |
| Gross Margin % | 96.53% | 100% | — | — |
| EBITDA Margin % | -1534.72% | -13200.92% | -4712.97% | -755.8% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-03-21 | 1:0.0833333 |